Etanercept
Etanercept is a fusion protein consisting of a recombinant tumour necrosis factor alpha receptor and the (Fc) constant region of human IgG1.
This molecule is able to bind both TNF-alpha and lymphotoxin (TNF-beta).
It is administered by twice weekly sub-cutaneous injection and is licensed for the treatment of rheumatoid arthritis and polyarticular juvenile idiopathic arthritis where treatment with other DMARDs including Methotrexate have failed.
Check the Summary of Product Characteristics before prescribing this drug.
Reference
- NICE. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Technology appraisal guidance TA375. Published January 2016
Related pages
- Dosage of etanercept
- Contra-indications in the use of etanercept
- Clinical efficacy of etanercept
- Side effects of etanercept
- NICE guidance - etanercept and efalizumab for the treatment of adults with psoriasis
- NICE guidance - etanercept , infliximab and adalimumab for the treatment of adults with psoriatic arthritis
- Monitoring etanercept
- NICE guidance - etanercept, infliximab and adalimumab for the treatment of adults with rheumatoid arthritis
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.